CompletedNot Applicable

Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.

Denmark, Finland, France183 participantsStarted 2018-08-16

Plain-language summary

This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical practice. Subjects who are receiving Naloxegol (prescribed by their physician according to the SmPC, which recommends that all currently used maintenance laxative therapy should be halted) during the enrolment period may be eligible for enrolment into the study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient ≥ 18 years old * Patient who is receiving treatment with opioids for at least 4 weeks, and is expected to remain on opioids for duration of study * Patient with opioid-induced constipation * Patient in whom the clinician plans treatment with Naloxegol according to routine clinical practice (Naloxegol SmPC recommends that all currently used maintenance laxative therapy should be halted) * Signing of the informed consent Exclusion Criteria: \- Patients with colorectal cancer

What they're measuring

To assess the safety and efficacy of Naloxegol in a real world setting in cancer patients.

Timeframe: 4 week treatment period

Trial details

NCT IDNCT03638440

SponsorKyowa Kirin Pharmaceutical Development Ltd

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-03-05

View on ClinicalTrials.gov More Opioid Induced Constipation trials